However, the presence of a phosphatase and tensin homolog (PTEN) or a serine/threonine kinase 11 (STK11) mutation was correlated with early progression in nonsmall cell lung cancer (NSCLC) patients receiving anti PD-1 IO. Here, STK11 is linked to non-small cell lung carcinoma.